U.S. eases enforcement for compounding six unapproved peptides

Reuters reports Health Secretary Robert F. Kennedy Jr. advanced an interim policy allowing licensed pharmacies and physicians to compound six unapproved peptides, including BPC-157 and TB-500. Regulators won't take enforcement action if compounders meet requirements for ingredient quality, manufacturing, labeling, safety reporting and patient-specific prescriptions. Compounded drugs are not FDA-approved. Public Citizen's Robert Steinbrook warned the move could expose patients to contamination, impurities and unknown side effects.